Previous 10 | Next 10 |
Trevena ( NASDAQ: TRVN ) has announced an offering of common stock and warrants priced at-the-market under Nasdaq rules. The biopharmaceutical company entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 2,614,380 s...
CHESTERBROOK, Pa., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it h...
Trevena, Inc. (TRVN) Q3 2022 Results Earnings Conference Call November 13, 2022, 08:00 AM ET Company Participants Barry Shin - Chief Financial Officer Carrie Bourdow - President and Chief Executive Officer Patty Drake - Chief Commercial Officer Mark Demitrack...
Trevena ( NASDAQ: TRVN ) slid 18% after the bell on Wednesday as the firm said it will implement a 1-for-25 reverse stock split . The reverse split will be effective at 5.01 pm ET on Nov. 9. Trevena's ( TRVN ) stock will begin trading on a split-adjusted basis ...
CHESTERBROOK, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has filed a Certificate of...
Trevena press release ( NASDAQ: TRVN ): Q3 GAAP EPS of -$0.09 in-line. Revenue of -$0.44M (-344.4% Y/Y) misses by $0.88M . “We are pleased that OLINVYK received CMS pass-through reimbursement for ambulatory surgical centers and hospital outpatient settings. ...
TRV045 demonstrated a favorable tolerability profile with no reported SAEs and no lymphopenia Nonclinical study showed anti-inflammatory signaling, suggesting a potential disease-modifying effect of TRV045 in the treatment of epilepsy, based on astrocyte cell culture study ...
OLINVYK commercialization progresses with Vizient contract and receipt of CMS outpatient pass-through reimbursement Positive Phase 1 topline results for TRV045, a novel S1P receptor modulator; no serious adverse events and PK profile supports anticipated once daily dosing ...
Trevena ( NASDAQ: TRVN ) is scheduled to announce Q3 earnings results on Wednesday, November 9th, before market open. The consensus EPS Estimate is -$0.08 (flat Y/Y) and the consensus Revenue Estimate is $0.44M (+144.4% Y/Y). Over the last 1 year, TRVN has beaten EPS...
CHESTERBROOK, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial...
News, Short Squeeze, Breakout and More Instantly...
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones Trevena further expects a $10 million reduction in liabilities associated with its ex-US royalty financing ...
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in...